Cargando…
EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY
PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Retina
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841849/ https://www.ncbi.nlm.nih.gov/pubmed/28196056 http://dx.doi.org/10.1097/IAE.0000000000001552 |
_version_ | 1783304811609849856 |
---|---|
author | Calvo, Pilar Ferreras, Antonio Al Adel, Fadwa Dangboon, Wantanee Brent, Michael H. |
author_facet | Calvo, Pilar Ferreras, Antonio Al Adel, Fadwa Dangboon, Wantanee Brent, Michael H. |
author_sort | Calvo, Pilar |
collection | PubMed |
description | PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. RESULTS: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 ± 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 μm (95% confidence interval, 227.5–254.6 μm) at baseline to 236.9 μm (95% confidence interval, 223.9–249.9 μm) at 1 week (P = 0.09), 238.9 μm (95% confidence interval, 225.5–252.3 μm) at 1 month (P = 0.44), and 248 μm (95% confidence interval, 232.4–260.8 μm) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 μm in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure ≥22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. CONCLUSION: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients. |
format | Online Article Text |
id | pubmed-5841849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Retina |
record_format | MEDLINE/PubMed |
spelling | pubmed-58418492018-03-20 EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY Calvo, Pilar Ferreras, Antonio Al Adel, Fadwa Dangboon, Wantanee Brent, Michael H. Retina Original Study PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled. Best-corrected visual acuity and central retinal thickness (CRT) measured by spectral-domain optical coherence tomography were recorded at 1 week preoperatively, and 1 week, 1 month, and 3 months after surgery. Adverse events were also recorded. RESULTS: Twenty-four eyes of 24 patients (17 [70.8%] men; mean age 63.7 ± 8.7 years) with mild nonproliferative DR (41.7%), moderate nonproliferative DR (33.3%), severe nonproliferative DR (16.7%), or treated proliferative DR (8.3%) were selected. After DEX treatment, mean CRT changed from 241.1 μm (95% confidence interval, 227.5–254.6 μm) at baseline to 236.9 μm (95% confidence interval, 223.9–249.9 μm) at 1 week (P = 0.09), 238.9 μm (95% confidence interval, 225.5–252.3 μm) at 1 month (P = 0.44), and 248 μm (95% confidence interval, 232.4–260.8 μm) at 3 months (P = 0.15). No eyes showed a postoperative increase >50 μm in the CRT at any visit. A 10% increase in CRT was found in 8.3% of eyes. Mean best-corrected visual acuity significantly improved from 0.37 (20/50) at baseline to 0.19 (20/30) at 1 week, 0.12 (20/25) at 1 month, and 0.12 (20/25) at 3 months (P < 0.001 for each comparison). Mean intraocular pressure before surgery was 13.8 mmHg, and none of the patients developed an intraocular pressure ≥22 mmHg at any visit. None of the patients developed any serious adverse events during the follow-up. CONCLUSION: These short-term results suggest that a single DEX injection intraoperatively after phacoemulsification could avoid an increase in CRT after cataract surgery in diabetic patients. Retina 2018-03 2017-02-10 /pmc/articles/PMC5841849/ /pubmed/28196056 http://dx.doi.org/10.1097/IAE.0000000000001552 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Study Calvo, Pilar Ferreras, Antonio Al Adel, Fadwa Dangboon, Wantanee Brent, Michael H. EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY |
title | EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY |
title_full | EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY |
title_fullStr | EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY |
title_full_unstemmed | EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY |
title_short | EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY |
title_sort | effect of an intravitreal dexamethasone implant on diabetic macular edema after cataract surgery |
topic | Original Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841849/ https://www.ncbi.nlm.nih.gov/pubmed/28196056 http://dx.doi.org/10.1097/IAE.0000000000001552 |
work_keys_str_mv | AT calvopilar effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery AT ferrerasantonio effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery AT aladelfadwa effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery AT dangboonwantanee effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery AT brentmichaelh effectofanintravitrealdexamethasoneimplantondiabeticmacularedemaaftercataractsurgery |